Damon Runyon News

An important reason why the United States is the global leader in biomedical research is that many of the best scientific minds from around the world come here to train and work.  If you walked into any leading US research laboratory today, you would meet scientists from many countries working together as a team to solve the greatest scientific challenge of all time – understanding human biology and ending suffering from disease.  These labs are meritocracies and melting pots.  Most importantly, they generate knowledge that drives our entire health care enterprise and saves lives.

By Victoria E.H. Wang, MD, PhD, Damon Runyon Fellow, University of California, San Francisco

The Damon Runyon Cancer Research Foundation recently asked some of our current award recipients how cancer will be prevented, diagnosed, and/or treated differently in the future. What can a future cancer patient, say 10-20 years from now, expect to experience? Their responses were fascinating, and over the next few months we will share their visions for the future on this blog.

Lorraine W. Egan, President and CEO, Damon Runyon Cancer Research Foundation

Gregg Gordon was 44 and the picture of health until he suddenly became excessively tired and noticed two small bumps on his shin. A visit to his doctor led to a startling cancer diagnosis, and less than 24 hours later he was receiving chemotherapy to treat acute myeloid leukemia.

When standard treatments failed, Gregg’s best hope was a bone marrow transplant, but he could not find a donor match. Fortunately, he was referred to Colleen Delaney, MD, in Seattle, who had developed a process for expanding stem cells from umbilical cord blood for use in patients without donors. As The Washington Post reported in September, the procedure was a success and Gregg has been cancer-free for five years. 

By Brian Shirts MD, PhD, Damon Runyon Innovator, University of Washington

The Damon Runyon Cancer Research Foundation recently asked some of our current award recipients how cancer will be prevented, diagnosed, and/or treated differently in the future. What can a future cancer patient, say 10-20 years from now, expect to experience? Their responses were fascinating, and over the next few months we will share their visions for the future on this blog.

Assistant Professor of Pediatrics at UCSF Dr. Amit Sabnis treats pediatric hematology and oncology patients. “The highs are much higher than the lows,” he said.  His training in pediatric oncology has taught him how to help  patients and their families find hope, make plans for the future and live the best life they can.  “Many times that involves a period of hard treatment and then a cure,” he said.

Thanks to support from the Damon Runyon-Sohn Pediatric Cancer Fellowship, Amit is not only caring for his patients in the clinic but also developing better treatments for them in the lab.  He is researching metastatic rhabdomyosarcoma (RMS), a rare muscle cancer that affects children.  Treatment for advanced RMS has not advanced in decades.

Peter Van Camp and his wife Laura Grant Van Camp are supporters of the Damon Runyon-Rachleff Innovation Award program through the Nadia’s Gift Foundation.  Peter also serves on the Damon Runyon Board of Directors, Scientific Committee and the Bay Area Committee.

Peter and Laura Van Camp believe Damon Runyon’s targeted strategy of supporting the best young scientists tackling innovative cancer research is a perfect match for the Bay Area.  A tech leader himself, Peter equates the Damon Runyon approach with Silicon Valley’s ethos of investing in innovators creating disruptive business models. “Their elite scientific board focused on funding top minds doing high risk-high reward research, coupled with a donor’s ability to develop a personal relationship with scientists they support, makes Damon Runyon unique,” Peter said.  Laura finds it compelling to “come in on the ground floor and see the impact their giving makes in real time.”   

By Arvin C. Dar, PhD, Damon Runyon Innovator, Icahn School of Medicine at Mount Sinai

The Damon Runyon Cancer Research Foundation recently asked some of our current award recipients how cancer will be prevented, diagnosed, and/or treated differently in the future. What can a future cancer patient, say 10-20 years from now, expect to experience? Their responses were fascinating, and over the next few months we will share their visions for the future on this blog.

Gregory L. Beatty, MD, PhD (Damon Runyon-Nadia’s Gift Foundation Innovator ’12-’15) and colleagues at the Abramson Cancer Center at University of Pennsylvania, Philadelphia, reported high levels of inflammatory compounds in mice with pancreatic tumors. These included CCL2, a signaling molecule that promotes recruitment of inflammatory white blood cells by tumors. This likely contributes to the protective tumor microenvironment that makes most pancreatic tumors resistant to treatment. CCL2 levels increased further after the mice received radiotherapy.

By Giada Bianchi, MD, Damon Runyon-Celgene Physician-Scientist

The Damon Runyon Cancer Research Foundation recently asked some of our current award recipients how cancer will be prevented, diagnosed, and/or treated differently in the future. What can a future cancer patient, say 10-20 years from now, expect to experience? Their responses were fascinating, and over the next few months we will share their visions for the future on this blog.

Theodora S. Ross, MD, PhD (Damon Runyon Scholar ’01-’03), and colleagues at UT Southwestern, Dallas, reported that the BRCA1 gene is required for the survival of blood forming stem cells. This could explain why patients with BRCA1 mutations do not have an elevated risk for leukemia; the stem cells die before they have an opportunity to transform into a blood cancer. These results also suggest that these patients may be at higher risk for the serious side effects of chemotherapy. The study was published in Cell Reports.